Bayer Spain today announced its results for the year 2023.
Today we greet you from #Berlimedour innovation and production center in Alcalá de Henares (Madrid), where today we will present the results and activity in Spain in 2023.
You can follow them on #DatosBayer2023 pic.twitter.com/pNlVkGL0tj
— Bayer Spain (@BayerSpain) April 17, 2024
Sales of the German laboratory in Spain have reached 768 million euros in 2023, 3% more than the previous year.
The ‘pharmaceuticals’ (prescription medicines) division “has maintained its growth, after a great 2022, increasing its sales this year by 1.8%, to 397 million.”
The ‘Crop Science’ division (agriculture) had a turnover of 256 million last year, 2.8% more: “This improvement responds to a growth in sales and market share as a whole for its activity and especially in the field of insecticides. “says the company.
While the ‘Consumer Health‘ division (self-care products) had a turnover of 115 million, 7.5% more in sales, with good results from brands such as Derma, in the Bepanthol/Bepanthen range, and Canesten range; and in the flu and cold area, the Propal, Desenfriol and Aspirin range.
It should be remembered that, worldwide, the German chemical and pharmaceutical giant sold 15.2% fewer birth control pills (potentially abortive) in 2023. Write, Yasmin y Yasminelle. While sales of SAYS Mirena, Kyleena and Jaydess They fell 5.3%, to 1,209 million, as reported by Hispanidad.
And that, after covering himself with chemical abortionnow he aspires to do the same with the trans business: had no qualms about sponsoring a trans children’s film while producing ‘feminizing’ drugs (specifically, cyproterone acetate, an antiandrogen that has been used to feminize men who want to be women).
Returning to Spain, in 2023, the pharmaceutical company invested a total of 154 million euros in our country. While in the last five years, Bayer has invested 423 million in Spain.
Bernard Kanahuati, CEO of Bayer in Spain and Portugal, stated: “Our trajectory has been strong and positions us very solidly in the present but also in the future due to our commitment to the challenges of tomorrow.” And after celebrating 125 years in our country, he noted: “This is also a moment to thank all the professionals who, with their work, have made our growth in the country possible over the years.”
In this context, it is worth highlighting the interest of the Generalitat of Catalonia in making this Spanish region an important center for research and development of international laboratories. For example, recently, AstraZeneca expanded its investment in Barcelona to 1.3 billion euros.